Invesco S&P 500 Momentum ETF vs Zimmer Biomet Holdings Inc — how do they compare? Invesco S&P 500 Momentum ETF trades at $150, while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Zimmer Biomet Holdings Inc pays a 1.07% dividend while Invesco S&P 500 Momentum ETF pays none, and Invesco S&P 500 Momentum ETF is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.
| SPMO | ZBH | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $161.66 | $107.71 |
52-Week Low | $107.84 | $79.58 |
Market Cap | — | $17.36B |
Enterprise Value | — | $24.40B |
Dividend Yield | — | 1.07% |
Signals from Pluang's Aura AI — not financial advice
SPMO trades at $144.50 with a slight 0.42% daily gain. Technical indicators show a bearish trend with moving averages signaling caution, though oscillators are neutral. Recent news highlights strong momentum performance, with the ETF gaining 7.5% in June 2026 and leading S&P factors. The portfolio is concentrated in technology stocks, benefiting from AI-driven growth but facing volatility risks.
Outlook remains mixed; AI momentum supports growth, but high concentration and bearish technicals pose risks. Investors should weigh the ETF's rules-based strategy against potential sector rotations. Dividend of $0.25 is scheduled for June 2026, adding income appeal amid market uncertainty.
No Aura AI signal available yet.
Trailing returns across standard periods
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →